Brief: SELLAS Life Sciences Announces Independent Data Monitoring Committee Post Completion Of Enrollment In Regal Phase III Study
29/04/2024 13:49
April 29 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE RECOMMENDATION OF
INDEPENDENT DATA MONITORING COMMITTEE FOLLOWING COMPLETION OF
ENROLLMENT IN REGAL PHASE 3 STUDY
* SELLAS LIFE SCIENCES GROUP INC: NEXT EFFICACY AND SAFETY
ASSESSMENT OF ALL REGAL PATIENTS (N=127) IN JUNE 2024
* SELLAS LIFE SCIENCES GROUP INC - IDMC RECOMMENDS
CONTINUATION OF
PHASE 3 REGAL TRIAL
Source text for Eikon: ID:nGNX5gDKfP
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses